23 results
Approaches to Evaluating Kidney Disease in Patients with HIV Infection #Pathophys #Nephro #IM #HIV #CKD #AKI
Infection #Pathophys #Nephro ... #IM #HIV #CKD # ... AKI #NEJM
Onset of Intramuscular (IM) Medications for Severe Agitation
Ketamine (2-5 mg/kg IM) 3-7m
Droperidol (5 mg IM) 5-10m
Midazolam
Intramuscular (IM ... Ketamine (2-5 mg/kg IM ... Droperidol (5 mg IM ... Agitation #Duration #Pharmacology ... #Table #Management
Nephron Remodeling as a Mechanism of Diuretic Resistance. When high doses of loop diuretics are used
Nephron Remodeling ... basis, the distal nephron ... of the distal nephron ... #IM #LoopDiuretic ... NephronRemodeling #NEJM
Pulmonary Embolism Severeity Index - estimates 30d mortality #Diagnosis #Management #EM #IM #PCC #PESI #sPESI #risk
mortality #Diagnosis #Management ... #EM #IM #PCC #PESI ... #sPESI #risk #score
Croup Management - Epinephrine Dosing
Use steroids appropriately, as needed
In older children with mild symptoms, may consider
Croup Management ... • Epinephrine IM ... 15 kg: 0.1 mg IM ... SarahFoohey #Croup #Management ... Epinephrine #dosing #pharmacology
Naloxone - Toxicology

Adult starting dose:
 - 0.4 mg IV/IM/IO/SQ for non-opioid dependent patients
 - 0.04 mg
- 0.4 mg IV/IM ... - 0.04 mg IV/IM ... - 0.1 mg/kg IV/IM ... Narcan #Toxicology #Management ... #Pharmacology #
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
End Points #EBM #Neuro ... #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Mechanisms of Loop Diuretic Action and Resistance. Panel A, loop diuretics circulate bound to protein. As
Pathophysiology #Nephro ... #IM #LoopDiuretic ... MechanismOfAction #Resistance #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
End Points #EBM #Neuro ... #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
Trial Group #EBM #Neuro ... #IM #Fremanezumab ... AdverseEvents #NEJM ... #NEJM